PD-L1 CRISPR Stable Knockout MC38 Cell Line
|T6149||1x106 cells / 1.0 ml|
PD-L1 CRISPR Stable Knockout MC38 Cell line is derived from a widely used murine colon carcinoma model, MC38. Guide RNAs (gRNA) carried on a gRNA cloning vector were used to target exon 1 of the mouse CD274 gene encoding Programmed death-ligand 1. Successful knockout of PD-L1 was verified by immunefluorescence after cells were subjected in interferon-gamma. Programmed death-ligand 1 (PD-L1) is known to be frequently expressed on both tumor cells and tumor-infiltrating immune cells and is implicated in the suppression of immune response via the induction of T-cell exhaustion. This line may be valuable for use in drug screen studies or in the investigation of PD-L1 related signaling and function.
|Species||Mouse (M. musculus)|
|Seeding Density||5,000 - 20,000 cells/cm2|
|Population Doubling Time||15 - 25 hours|
For Research Use Only
|Unit quantity||1x106 cells / 1.0 ml|
|Cell Type||Drug Discovery Cell Lines|
Use of PriCoatTM T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) is required for cell adhesion to the culture vessels. Grow cells in ECM-coated culture vessels unless otherwise specified in the Propagation Requirements below.
The base medium for this cell line is Prigrow V medium available at abm, Cat. No. TM015. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (TM999)* to a final concentration of 8%, Penicillin/Streptomycin Solution (G255) to a final concentration of 1%, and L-glutamine (G275) to a final concentration of 2 mM.
1. For for-profit organizations and corporations, please contact [email protected] for pricing of this item.
2. Sale of this item is subjected to the completion of a Material Transfer Agreement (MTA) by the purchasing individual/institution for each order. If you have any questions regarding this, please contact us at [email protected].
3. All test parameters provided in the CoA are conducted using abm's standardized culture system and procedures. The stated values may vary under the end-user's culture conditions. Please verify that the product is suitable for your studies by referencing published papers or ordering RNA (0.5 μg, Cat.# C207, $450.00) or cell lysate (100 μg, Cat.# C206, $600.00) to perform preliminary experiments, or alternatively use our Gene Expression Assay Service (Cat# C138). All sales are final.
4. We recommend live cell shipments for ease of cell transfer and this option can be requested at the time of ordering. Please note that the end-user will need to evaluate the feasibility of live cell shipment by taking into account the final destination's temperature variation and its geographical location. In addition, we thoroughly test our cell lines for freeze-thaw recovery. If frozen cells were received and not recovered in your lab under the exact, specified conditions (using recommended culture vessel, media, additional supplements, and atmospheric conditions), a live cell replacement is possible at a cost (plus shipping).
5. All of abm's cell biology products are for research use ONLY and NOT for therapeutic/diagnostic applications. abm is not liable for any repercussions arising from the use of its cell biology product(s) in therapeutic/diagnostic application(s). Please contact a technical service representative for more information.
6. abm makes no warranties or representations as to the accuracy of the information on this site. Citations from literature and provided for informational purposes only. abm does not warrant that such information has been shown to be accurate.
7. abm warrants that cell lines shall be viable upon initiation of culture for a period of thirty (30) days after shipment and that they shall meet the specifications on the applicable abm Material Product Information sheet, certificate of analysis, and/or catalog description. Such thirty (30) day period is referred to herein as the "Warranty Period."
|Depositor||Leiden University Medical Centre|
- Kleinovink, K. "PD-L1 expression on malignant cells is no prerequisite for checkpoint therapy" Oncoimmunology 6(4):1 (2017). DOI: 10.1080/2162402X.2017.1294299.